GeneBioTech Co. ,Ltd (KOSDAQ:086060)
South Korea
· Delayed Price · Currency is KRW 4,780.00
-35.00 (-0.73%)
At close: Apr 28, 2026
GeneBioTech Co. ,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 90,789 | 82,959 | 79,477 | 82,759 | 62,814 | Upgrade
|
| Other Revenue | - | - | - | -0 | -0 | Upgrade
|
| Revenue | 90,789 | 82,959 | 79,477 | 82,759 | 62,814 | Upgrade
|
| Revenue Growth (YoY) | 9.44% | 4.38% | -3.96% | 31.75% | 6.25% | Upgrade
|
| Cost of Revenue | 76,533 | 69,589 | 65,825 | 72,409 | 55,374 | Upgrade
|
| Gross Profit | 14,256 | 13,370 | 13,652 | 10,349 | 7,439 | Upgrade
|
| Selling, General & Admin | 8,845 | 8,285 | 8,411 | 7,446 | 6,472 | Upgrade
|
| Research & Development | 894.56 | 875.1 | 837.22 | 765.04 | 820.81 | Upgrade
|
| Amortization of Goodwill & Intangibles | 67.9 | 65.9 | 63.18 | 39.68 | 12.16 | Upgrade
|
| Other Operating Expenses | 92.32 | 102.78 | 104.84 | 108.26 | 106.95 | Upgrade
|
| Operating Expenses | 10,260 | 9,526 | 9,679 | 8,792 | 7,893 | Upgrade
|
| Operating Income | 3,996 | 3,844 | 3,973 | 1,557 | -453.15 | Upgrade
|
| Interest Expense | -562.44 | -642.98 | -581.38 | -276.45 | -152 | Upgrade
|
| Interest & Investment Income | 777.74 | 800.59 | 669.56 | 263.92 | 127.25 | Upgrade
|
| Currency Exchange Gain (Loss) | 129.98 | -639.97 | -138.66 | 23.26 | -223.24 | Upgrade
|
| Other Non Operating Income (Expenses) | 74.01 | 19.06 | 20.65 | 247.09 | -129.9 | Upgrade
|
| EBT Excluding Unusual Items | 4,415 | 3,380 | 3,943 | 1,815 | -831.03 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.15 | 122.26 | 20.69 | -0 | -5.88 | Upgrade
|
| Asset Writedown | - | - | -589.54 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.85 | Upgrade
|
| Pretax Income | 4,415 | 3,503 | 3,374 | 1,815 | -837.76 | Upgrade
|
| Income Tax Expense | 625.88 | 637.3 | 782.7 | 291.39 | -353.36 | Upgrade
|
| Earnings From Continuing Operations | 3,789 | 2,865 | 2,591 | 1,523 | -484.4 | Upgrade
|
| Net Income to Company | 3,789 | 2,865 | 2,591 | 1,523 | -484.4 | Upgrade
|
| Net Income | 3,789 | 2,865 | 2,591 | 1,523 | -484.4 | Upgrade
|
| Net Income to Common | 3,789 | 2,865 | 2,591 | 1,523 | -484.4 | Upgrade
|
| Net Income Growth | 32.23% | 10.57% | 70.12% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Change (YoY) | 0.08% | -0.07% | - | - | - | Upgrade
|
| EPS (Basic) | 440.00 | 333.00 | 300.95 | 176.91 | -56.26 | Upgrade
|
| EPS (Diluted) | 440.00 | 333.00 | 300.95 | 176.91 | -56.26 | Upgrade
|
| EPS Growth | 32.13% | 10.65% | 70.12% | - | - | Upgrade
|
| Free Cash Flow | 3,856 | -1,564 | 6,838 | -4,834 | -5,816 | Upgrade
|
| Free Cash Flow Per Share | 447.85 | -181.81 | 794.19 | -561.41 | -675.39 | Upgrade
|
| Gross Margin | 15.70% | 16.12% | 17.18% | 12.50% | 11.84% | Upgrade
|
| Operating Margin | 4.40% | 4.63% | 5.00% | 1.88% | -0.72% | Upgrade
|
| Profit Margin | 4.17% | 3.45% | 3.26% | 1.84% | -0.77% | Upgrade
|
| Free Cash Flow Margin | 4.25% | -1.89% | 8.60% | -5.84% | -9.26% | Upgrade
|
| EBITDA | 5,382 | 5,212 | 5,311 | 2,843 | 791.25 | Upgrade
|
| EBITDA Margin | 5.93% | 6.28% | 6.68% | 3.44% | 1.26% | Upgrade
|
| D&A For EBITDA | 1,387 | 1,368 | 1,338 | 1,286 | 1,244 | Upgrade
|
| EBIT | 3,996 | 3,844 | 3,973 | 1,557 | -453.15 | Upgrade
|
| EBIT Margin | 4.40% | 4.63% | 5.00% | 1.88% | -0.72% | Upgrade
|
| Effective Tax Rate | 14.18% | 18.20% | 23.20% | 16.06% | - | Upgrade
|
| Advertising Expenses | 109.97 | 127.26 | 54.49 | 429.28 | 429.72 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.